VDR FokI — The Vitamin D Receptor Activity Switch
The vitamin D receptor | A nuclear receptor protein that binds active vitamin D (calcitriol) and directly regulates the expression of hundreds of genes throughout the body (VDR) is
the master mediator of vitamin D's effects in nearly every tissue — from bones and
intestines to immune cells and the brain. The FokI variant (rs2228570) is unique
among VDR polymorphisms because it actually changes the protein structure, not just
expression levels. A single nucleotide change at the translation start codon
determines whether your cells produce a shorter, more transcriptionally active
receptor or a longer, less active one. This makes FokI the only VDR variant with a
clear, direct functional mechanism.
The Mechanism
The FokI polymorphism sits at the first of two potential translation initiation codons | ATG sequences where the ribosome can begin building the protein; the first ATG produces a 427-amino-acid protein, while the second produces a 424-amino-acid version
(ATG) in the VDR gene. When the G allele is present (on the plus strand; C on
the coding strand), the first ATG is abolished, forcing translation to begin at
the second ATG three codons downstream. This produces a VDR protein that is
three amino acids shorter (424 vs 427 amino acids). The shorter protein, designated
"F" in the classical nomenclature, binds more efficiently to transcription factor IIB | TFIIB: a general transcription factor that helps position RNA polymerase II at gene promoters; tighter VDR-TFIIB binding means more efficient gene activation
(TFIIB), resulting in approximately 1.7-fold greater transcriptional activity | Arai H et al. A vitamin D receptor gene polymorphism in the translation initiation codon. J Bone Miner Res, 1997
compared to the longer "f" form.
Crucially, FokI is independent of the other well-known VDR polymorphisms (BsmI,
ApaI, TaqI), which are clustered in the 3' end of the gene and are in strong
linkage disequilibrium | LD: the tendency of nearby genetic variants to be inherited together; FokI shows no meaningful LD with BsmI/ApaI/TaqI because it sits far away in exon 2
with each other. FokI, located in exon 2, segregates independently — so your FokI
genotype tells you something that your BsmI genotype cannot.
The Evidence
The functional significance of FokI was established by
Arai et al. | Arai H et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity. Biochem Biophys Res Commun, 1997
who demonstrated in cell-based assays that the shorter VDR protein (F/G allele)
drives significantly stronger transcriptional activation of vitamin D target genes.
This finding has been replicated in immune cells, where the F allele shows stronger
induction of VDR-dependent antimicrobial peptides.
A meta-analysis of VDR polymorphisms and osteoporosis | Zhao L et al. VDR polymorphisms and postmenopausal osteoporosis, 2018
found the FokI variant associated with osteoporosis risk (OR 1.19 overall), with
stronger effects in Asian populations. Individuals with the less active receptor
(AA genotype) showed reduced calcium absorption and lower bone mineral density
in multiple studies.
FokI has been extensively studied in immune function. A
meta-analysis of tuberculosis susceptibility | Selvaraj P et al. FokI VDR and tuberculosis, 2021
found the ff genotype (AA on 23andMe) associated with increased TB risk (OR 1.36,
95% CI 1.11-1.66), particularly in Asian populations (OR 2.0). The mechanism is
straightforward: vitamin D activates monocytes and stimulates antimicrobial
peptide production through VDR, and the less active receptor blunts this response.
Cancer associations have also been documented. An updated meta-analysis of 39 studies | Xu G et al. VDR FokI and colorectal cancer, 2018
found a borderline association between FokI and colorectal cancer risk, while
breast cancer meta-analyses showed the ff genotype associated with approximately
14% increased risk. Vitamin D's anti-proliferative effects are mediated through
VDR, so reduced receptor activity could weaken this protective mechanism.
A systematic review of vitamin D supplementation response | Jolliffe DA et al. VDR polymorphisms and vitamin D supplementation response, 2022
found that FokI genotype modifies the response to vitamin D supplementation, with
FF carriers (GG on 23andMe) showing better clinical responses to supplementation.
Practical Implications
If you carry one or two copies of the A allele, your vitamin D receptor is less
transcriptionally active. This does not mean vitamin D is ineffective for you — it
means you may need to maintain higher circulating vitamin D levels to achieve the
same downstream biological effects. The key actions are:
Maintain optimal vitamin D status through regular testing. Aim for 25(OH)D levels
of 40-50 ng/mL rather than settling for the minimum 30 ng/mL, especially if you
carry two A alleles. Use vitamin D3 (cholecalciferol), taken with a fat-containing
meal for optimal absorption. Ensure adequate calcium intake, since reduced VDR
activity impairs intestinal calcium absorption.
Pay attention to immune health. The reduced receptor activity may mean you benefit
more from maintaining robust vitamin D levels during winter months and illness
seasons, when immune demands on the vitamin D system are highest.
Interactions
FokI interacts with VDR BsmI (rs1544410) and CYP2R1 (rs10741657). While FokI is
genetically independent of BsmI (no linkage disequilibrium), their effects on
vitamin D signaling can compound. If you carry FokI A alleles (less active receptor)
AND BsmI T alleles (reduced receptor expression), you face a "double hit" — fewer
receptors AND less active ones. Similarly, carrying CYP2R1 risk alleles (reduced
vitamin D activation) on top of FokI A alleles means less active vitamin D reaching
a less responsive receptor. In such combined scenarios, aggressive vitamin D
optimization (higher target levels, consistent supplementation, regular monitoring)
becomes particularly important.
All Genotypes
More active vitamin D receptor — optimal vitamin D signaling
You have two copies of the G allele (FF genotype in classical notation). Your vitamin D receptor protein is the shorter, more transcriptionally active form, with approximately 1.7-fold greater activity than the longer variant. This means your cells respond more efficiently to circulating vitamin D. About 45% of people globally share this genotype. It is the most common genotype in most populations, especially in Africa (~65%) and Europe (~38%).
Intermediate vitamin D receptor activity — one active and one less active copy
You carry one G allele and one A allele (Ff heterozygote). Your cells produce a mix of the shorter, more active VDR protein and the longer, less active form. This gives you intermediate receptor activity — somewhat reduced compared to GG but substantially better than AA. This is the most common genotype worldwide, shared by about 44% of people globally. It is especially prevalent in European populations (~47%).
Less active vitamin D receptor — reduced signaling efficiency
You have two copies of the A allele (ff genotype in classical notation). Your vitamin D receptor protein is the longer, less transcriptionally active form. This means your cells are less responsive to circulating vitamin D, even when blood levels are adequate. About 11% of people globally share this genotype. It is most common in Latino populations (~23%) and least common in African populations (~4%).